KR20230098053A - Composition for preventing, ameliorating or treating respiratory disease comprising Cardamine flexuosa extract as effective component - Google Patents
Composition for preventing, ameliorating or treating respiratory disease comprising Cardamine flexuosa extract as effective component Download PDFInfo
- Publication number
- KR20230098053A KR20230098053A KR1020220181540A KR20220181540A KR20230098053A KR 20230098053 A KR20230098053 A KR 20230098053A KR 1020220181540 A KR1020220181540 A KR 1020220181540A KR 20220181540 A KR20220181540 A KR 20220181540A KR 20230098053 A KR20230098053 A KR 20230098053A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- radish
- respiratory diseases
- preventing
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 26
- 244000079471 Cardamine flexuosa Species 0.000 title claims description 3
- 235000008477 Cardamine flexuosa Nutrition 0.000 title claims description 3
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 235000013376 functional food Nutrition 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 12
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 9
- 208000006673 asthma Diseases 0.000 claims abstract description 7
- 239000003674 animal food additive Substances 0.000 claims abstract description 5
- 241000220259 Raphanus Species 0.000 claims description 29
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 23
- 229940092385 radish extract Drugs 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 241000272194 Ciconiiformes Species 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 240000003291 Armoracia rusticana Species 0.000 claims description 6
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 4
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 201000008197 Laryngitis Diseases 0.000 claims description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 3
- 201000007100 Pharyngitis Diseases 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 206010044008 tonsillitis Diseases 0.000 claims description 3
- 206010009152 Chronic tonsillitis Diseases 0.000 claims description 2
- 201000009243 chronic laryngitis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims 1
- 240000007651 Rubus glaucus Species 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 29
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 28
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 18
- 101710085496 C-X-C motif chemokine 2 Proteins 0.000 description 16
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 description 16
- 102100038138 WD repeat-containing protein 26 Human genes 0.000 description 16
- 230000000241 respiratory effect Effects 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 102100022496 Mucin-5AC Human genes 0.000 description 12
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- -1 CXCL-1 Proteins 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 241000208125 Nicotiana Species 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 102000013691 Interleukin-17 Human genes 0.000 description 7
- 108050003558 Interleukin-17 Proteins 0.000 description 7
- 241000226211 Salminus brasiliensis Species 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 230000023385 chemokine (C-C motif) ligand 5 production Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000037656 Respiratory Sounds Diseases 0.000 description 4
- 206010047924 Wheezing Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 description 3
- 102000001327 Chemokine CCL5 Human genes 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 244000235659 Rubus idaeus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241001164374 Calyx Species 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101150031922 MUC5AC gene Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229940042472 mineral oil Drugs 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 235000011305 Capsella bursa pastoris Nutrition 0.000 description 1
- 240000008867 Capsella bursa-pastoris Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000120694 Thestor Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방, 개선 또는 치료용 조성물에 관한 것으로, 상기 황새냉이 추출물이 호흡기 세포인 기관지 상피세포로부터 염증유도 매개인자인 케모카인 RANTES의 생성량을 감소시키는 효과가 있으므로, 천식 또는 만성폐쇄성폐질환(COPD)을 포함하는 호흡기질환의 건강기능식품, 의약품 또는 사료첨가제로 유용하게 사용될 수 있다.The present invention relates to a composition for preventing, ameliorating or treating respiratory diseases containing a storus extract as an active ingredient. Since it is effective, it can be usefully used as a health functional food, medicine, or feed additive for respiratory diseases including asthma or chronic obstructive pulmonary disease (COPD).
Description
본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention, improvement or treatment of respiratory diseases containing an extract of Dorado radish as an active ingredient.
천식, 만성폐쇄성폐질환, 알레르기비염, 진해 거담, 급만성기관지염, 세기관지염, 인후염, 편도염, 후두염 등은 호흡기질환의 대표적인 질환이다. 천식(asthma)은 기도, 특별히, 기관지에 생기는 만성 염증을 일컫는다. 천식으로 인해 유발되는 염증은 매연, 알레르기성 항원, 찬바람, 운동, 호흡기 감염 등 매우 다양한 소인에 의하여 악화될 수 있으며, 지속적인 염증은 기도의 변형 및 기도의 과민성(hyper-responsiveness)을 야기한다. 이러한 원인들에 의하여 천명(wheezing, 기도가 좁아져 쌕쌕거리거나 가랑가랑하는 호흡음이 나타나는 증상)이나, 숨이 차고 기침이 나며, 과도한 객담이 배출되는 등의 일반적인 증상이 나타난다. Asthma, chronic obstructive pulmonary disease, allergic rhinitis, cough, cough, acute and chronic bronchitis, bronchiolitis, sore throat, tonsillitis, laryngitis, etc. are typical respiratory diseases. Asthma refers to chronic inflammation of the airways, particularly the bronchi. Inflammation caused by asthma can be aggravated by a wide variety of factors such as smoke, allergens, cold wind, exercise, and respiratory infections, and continuous inflammation causes airway deformation and airway hyper-responsiveness. Due to these causes, common symptoms such as wheezing (a symptom in which the airway is narrowed and wheezing or purring breath sounds appear), shortness of breath, coughing, and excessive sputum discharge appear.
호흡기도는 크게 점막과 기관지평활근이라는 근육으로 이루어져 있고 점막에는 많은 분비샘들이 있어 필요한 분비물을 계속 분비하고 있으며 기관지 평활근이 수축하면 호흡기도가 좁아지게 된다. 매연, 알레르기성 항원, 찬바람, 운동, 호흡기 감염 등 매우 다양한 소인에 의하여 염증반응이 일어나면 분비샘에서 나오는 분비물이 더욱 증가하게 되고 이 분비물이 기도를 막아 점막이 기도 안쪽으로 부어오르게 되어 기도를 더욱 좁게 만든다. 이로 인해, 천명을 동반한 발작적인 기침과 호흡곤란이 심하게 나타나며, 발작 시에는 마른기침이 발생되고 흉부압박감을 느끼게 된다. 천명이 없이 만성적 기침과 흉부압박감이 있는 원인을 알 수 없는 호흡곤란 증상만 있는 천식도 많은데 이 증상들은 일상생활 중에서 갑자기 발작적으로 나타나는 경향이 있다.The respiratory tract is largely composed of a mucous membrane and a muscle called bronchial smooth muscle, and there are many glands in the mucous membrane that continuously secrete necessary secretions. When the bronchial smooth muscle contracts, the respiratory airway narrows. When an inflammatory reaction occurs due to a wide variety of factors such as smoke, allergens, cold wind, exercise, and respiratory infections, the secretion from the glands further increases, and this secretion blocks the airway, causing the mucous membrane to swell into the airway, further narrowing the airway. . As a result, paroxysmal coughing accompanied by wheezing and difficulty in breathing appear severely, and during seizures, dry cough occurs and chest pressure is felt. There are many asthmatic patients who have only symptoms of chronic cough and chest tightness without wheezing and unexplained dyspnea, but these symptoms tend to appear suddenly and paroxysmal during daily life.
한편, 황새냉이(Cardamine flexuosa)는 논밭 근처와 습지에서 자란다. 밑에서부터 가지가 갈라져서 퍼지고 높이 10∼30cm이며 밑부분은 털이 있고 검은 자주색이다. 잎은 어긋나고 깃꼴겹잎이다. 작은잎은 7∼17개이고 달걀 모양 또는 넓은 달걀 모양이며 끝의 작은잎이 가장 크다. 꽃은 4∼5월에 피고 백색이며 20개 내외의 꽃이 총상꽃차례로 달린다. 십자 모양의 꽃이 10여 송이 정도 달린다. 꽃받침은 4개이고 흑자색이 돌며 꽃잎은 꽃받침보다 2배 정도 길다. 꽃잎의 모양의 달걀을 거꾸로 세운 모양이다. 6개의 수술 중 4개가 길고 열매는 각과로 길이 2cm, 지름 1mm 정도로서 털이 없으며, 성숙하면 두 조각으로 갈라져서 뒤로 말린다. 어린 순을 나물로 한다. 동아시아·히말라야·유럽 및 북아메리카의 온대에서 난대에 걸쳐 분포한다.On the other hand, cardamine flexuosa grows near rice fields and in wetlands. Branches diverge and spread from the bottom, 10 to 30 cm high, and the lower part has hairs and is black purple. The leaves are alternate and pinnate compound leaves. There are 7 to 17 small leaves, egg-shaped or broad egg-shaped, and the small leaf at the end is the largest. Flowers bloom in April-May, are white, and about 20 flowers run in raceme. It has about 10 cross-shaped flowers. There are 4 calyxes, black purple, and petals are twice as long as calyxes. It looks like an upside-down egg in the shape of a petal. Four of the six stamens are long, and the fruit is a keratin, 2cm long and 1mm in diameter, hairless. When mature, it is split into two pieces and dried backwards. Use young shoots as herbs. Distributed from temperate to temperate zones in East Asia, the Himalayas, Europe and North America.
황새냉이 추출물 관련 기술로, 한국공개특허 제2021-0145578호에 큰황새냉이 추출물을 포함하는 피부 보습용 화장료 조성물이 개시되어 있으나, 아직까지는 본 발명의 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방, 개선 또는 치료용 조성물에 대하여 언급된 바 없다.As a technique related to the extract of Stork radish, Korean Patent Publication No. 2021-0145578 discloses a cosmetic composition for moisturizing skin containing an extract of Stork radish. There is no mention of a preventive, ameliorative or therapeutic composition.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방, 개선 또는 치료용 조성물을 제공하고, 상기 황새냉이 추출물이 호흡기 세포인 기관지 상피세포로부터 염증유발 매개인자인 케모카인 RANTES의 생성량을 감소시키며, 염증성 사이토카인(IL-6, TNF-α 및 MUC5AC)의 발현량을 감소시키는 효과가 있을 뿐만 아니라, 동물모델에서 총 BAL 세포 수 및 BAL 내 호중구 수를 감소시키며, BALF 내의 IL-1α, TNF-α, IL-17, MIP2, CXCL-1의 함량을 감소시키고, TNF-α, MIP2, CXCL-1, MUC5AC 유전자 발현량을 감소시키는 효과가 있으며, 폐조직 손상억제 효과가 있다는 것을 확인함으로써, 본 발명을 완성하였다.The present invention has been derived from the above needs, and the present invention provides a composition for preventing, improving or treating respiratory diseases containing a storus radish extract as an active ingredient, and the stor radish extract is a respiratory cell, bronchial epithelial cell. It reduces the production of chemokine RANTES, a mediator of inflammation, and reduces the expression of inflammatory cytokines (IL-6, TNF-α and MUC5AC). It has the effect of reducing the number of neutrophils, reducing the content of IL-1α, TNF-α, IL-17, MIP2, and CXCL-1 in BALF, and reducing the expression level of TNF-α, MIP2, CXCL-1, and MUC5AC genes And, by confirming that there is an effect of inhibiting lung tissue damage, the present invention was completed.
상기 목적을 달성하기 위하여, 본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a health functional food composition for preventing or improving respiratory diseases containing a storus extract as an active ingredient.
또한, 본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of respiratory diseases containing a dorado extract as an active ingredient.
또한, 본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방 또는 치료용 수의학적 조성물을 제공한다.In addition, the present invention provides a veterinary composition for the prevention or treatment of respiratory diseases containing a storus extract as an active ingredient.
또한, 본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방 또는 개선용 사료첨가제를 제공한다.In addition, the present invention provides a feed additive for preventing or improving respiratory diseases containing the extract of radish radish as an active ingredient.
본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방, 개선 또는 치료용 조성물에 관한 것으로, 상기 황새냉이 추출물이 호흡기 세포인 기관지 상피세포로부터 염증유발 매개인자인 케모카인 RANTES의 생성량을 감소시키며, 염증성 사이토카인(IL-6, TNF-α 및 MUC5AC)의 발현량을 감소시키는 효과가 있을 뿐만 아니라, 동물모델에서 총 BAL 세포 수 및 BAL 내 호중구 수를 감소시키며, BALF 내의 IL-1α, TNF-α, IL-17, MIP2, CXCL-1의 함량을 감소시키고, TNF-α, MIP2, CXCL-1, MUC5AC 유전자 발현량을 감소시키는 효과가 있으며, 폐조직 손상억제 효과가 있다.The present invention relates to a composition for preventing, ameliorating or treating respiratory diseases containing a storus extract as an active ingredient. , not only has the effect of reducing the expression level of inflammatory cytokines (IL-6, TNF-α and MUC5AC), but also reduces the total number of BAL cells and the number of neutrophils in BAL in animal models, IL-1α and TNF in BALF It has the effect of reducing the content of -α, IL-17, MIP2, and CXCL-1, and the expression level of TNF-α, MIP2, CXCL-1, and MUC5AC genes, and has the effect of inhibiting lung tissue damage.
도 1은 기관지상피세포(BEAS-2B)에서, 황새냉이 추출물의 처리에 따른 RANTES 생성율을 확인한 결과이다. Dexa는 양성대조군으로 덱사메타손(dexamethasone) 0.5μM을 처리한 군이다. ###은 대조군(Control) 대비 10ng/㎖의 TNF-α 처리군에서의 RANTES 생성율이 통계적으로 유의미하게 증가하였다는 것으로, p<0.001이고, ***은 10ng/㎖의 TNF-α 처리군 대비 황새냉이 추출물 처리 군 및 양성대조군(Dexa)에서의 RANTES 생성율이 통계적으로 유의미하게 감소하였다는 것으로, p<0.001이다.
도 2는 기관지상피세포에서 LPS로 염증을 유도한 후, 염증성 사이토카인 IL-6의 발현량 변화를 확인한 결과이다. ###은 Control(정상 대조군) 대비 LPS 처리군(LPS20)의 IL-6 발현량이 통계적으로 유의미하게 증가하였다는 것으로, p<0.001이고, ***은 LPS 군 대비 본 발명의 50㎍/㎖의 황새냉이 추출물 처리군(CF50)의 IL-6 발현량이 통계적으로 유의미하게 감소하였다는 것으로, p<0.001이다.
도 3은 기관지상피세포에서 LPS로 염증을 유도한 후, 염증성 사이토카인 TNF-α의 발현량 변화를 확인한 결과이다. ###은 Control(정상 대조군) 대비 LPS 처리군(LPS20)의 TNF-α 발현량이 통계적으로 유의미하게 증가하였다는 것으로, p<0.001이고, ***은 LPS 군 대비 본 발명의 50㎍/㎖의 황새냉이 추출물 처리군(CF50)의 TNF-α 발현량이 통계적으로 유의미하게 감소하였다는 것으로, p<0.001이다.
도 4는 기관지상피세포에서 LPS로 염증을 유도한 후, 염증성 사이토카인 MUC5AC의 발현량 변화를 확인한 결과이다. ###은 Control(정상 대조군) 대비 LPS 처리군(LPS20)의 MUC5AC 발현량이 통계적으로 유의미하게 증가하였다는 것으로, p<0.001이고, **은 LPS 군 대비 본 발명의 50㎍/㎖의 황새냉이 추출물 처리군의 MUC5AC 발현량이 통계적으로 유의미하게 감소하였다는 것으로, p<0.01이다.
도 5는 호흡기 손상 동물모델을 이용하여 본 발명의 황새냉이 추출물의 효과를 확인하는 실험일정을 나타낸 개략도이다.
도 6은 호흡기 손상 동물모델에 본 발명의 황새냉이 추출물을 투여한 후 총 BAL 세포 수를 확인한 결과이다. ###은 정상군 대비 LPS+CS(표준 담배 추출물)로 유도한 호흡기 손상 대조군의 총 BAL 세포수가 통계적으로 유의미하게 증가하였다는 것으로, p<0.001이고, **, ***은 대조군 대비 본 발명의 황새냉이 추출물 투여군 또는 양성대조군의 총 BAL 세포수가 통계적으로 유의미하게 감소하였다는 것으로, **는 p<0.01이고, ***는 p<0.001이다.
도 7은 호흡기 손상 동물모델에 본 발명의 황새냉이 추출물을 투여한 후 BAL 내 호중구 수를 확인한 결과이다. ###은 정상군 대비 LPS+CS(표준 담배 추출물)로 유도한 호흡기 손상 대조군의 BAL 내 호중구 수가 통계적으로 유의미하게 증가하였다는 것으로, p<0.001이고, ***은 대조군 대비 본 발명의 황새냉이 추출물 투여군 또는 양성대조군의 BAL 내 호중구 수가 통계적으로 유의미하게 감소하였다는 것으로, p<0.001이다.
도 8은 호흡기 손상 동물모델에 본 발명의 황새냉이 추출물을 투여한 후 BALF 내의 IL-1α, TNF-α, IL-17, MIP2, CXCL-1의 함량을 확인한 결과이다. ##, ###은 정상군 대비 LPS+CS(표준 담배 추출물)로 유도한 호흡기 손상 대조군의 BALF 내의 IL-1α, TNF-α, IL-17, MIP2, CXCL-1의 함량이 통계적으로 유의미하게 증가하였다는 것으로, ##은 p<0.01이고, ###은 p<0.001이다. *, **은 대조군 대비 본 발명의 황새냉이 추출물 투여군 또는 양성대조군에서 BALF 내의 IL-1α, TNF-α, IL-17, MIP2, CXCL-1의 함량이 통계적으로 유의미하게 감소하였다는 것으로, *는 p<0.05이고, **는 p<0.01이다.
도 9는 호흡기 손상 동물모델에 본 발명의 황새냉이 추출물을 투여한 후 폐조직에서 TNF-α, MIP2, CXCL-1, MUC5AC 유전자 발현량을 확인한 결과이다. ##, ###은 정상군 대비 LPS+CS(표준 담배 추출물)로 유도한 호흡기 손상 대조군의 폐조직에서 TNF-α, MIP2, CXCL-1, MUC5AC 유전자 발현량이 통계적으로 유의미하게 증가하였다는 것으로, ##은 p<0.01이고, ###은 p<0.001이다. *, **은 대조군 대비 본 발명의 황새냉이 추출물 투여군 또는 양성대조군의 폐조직에서 TNF-α, MIP2, CXCL-1, MUC5AC 유전자 발현량이 통계적으로 유의미하게 감소하였다는 것으로, *는 p<0.05이고, **는 p<0.01이다.
도 10은 호흡기 손상 동물모델에 본 발명의 황새냉이 추출물 투여한 후 폐조직의 병리적 손상억제를 확인한 H&E 염색 및 M-T 염색 결과이다. Figure 1 is a result of confirming the RANTES production rate according to the treatment of dorado radish extract in bronchial epithelial cells (BEAS-2B). Dexa is a positive control group treated with 0.5 μM of dexamethasone. ### indicates a statistically significant increase in the RANTES production rate in the 10ng/ml TNF-α treated group compared to the control group, p<0.001, and *** indicates a 10ng/ml TNF-α treated group It means that the rate of RANTES production in the contrast radish radish extract treatment group and the positive control group (Dexa) decreased statistically significantly, p <0.001.
Figure 2 is the result of confirming the change in the expression level of the inflammatory cytokine IL-6 after inducing inflammation with LPS in bronchial epithelial cells. ### indicates a statistically significant increase in the IL-6 expression level of the LPS-treated group (LPS20) compared to the control (normal control), p<0.001, and *** indicates that the LPS group compared to the
Figure 3 is the result of confirming the change in the expression level of the inflammatory cytokine TNF-α after inducing inflammation with LPS in bronchial epithelial cells. ### indicates a statistically significant increase in TNF-α expression level in the LPS-treated group (LPS20) compared to the Control (normal control group), p<0.001, and *** is 50 μg/ml of the present invention compared to the LPS group , p<0.001, indicating that the TNF-α expression level of the radish radish extract treatment group (CF50) decreased statistically significantly.
Figure 4 is the result of confirming the change in the expression level of the inflammatory cytokine MUC5AC after inducing inflammation with LPS in bronchial epithelial cells. ### indicates a statistically significant increase in MUC5AC expression level in the LPS-treated group (LPS20) compared to the Control (normal control group), p<0.001, and ** indicates that 50 μg/ml of the present invention compared to the LPS group It means that the MUC5AC expression level of the extract treatment group decreased statistically significantly, p<0.01.
Figure 5 is a schematic diagram showing an experimental schedule for confirming the effect of the storus radish extract of the present invention using a respiratory injury animal model.
Figure 6 is a result of confirming the total number of BAL cells after administering the storus extract of the present invention to a respiratory injury animal model. ### indicates a statistically significant increase in the total number of BAL cells in the respiratory injury control group induced by LPS + CS (standard tobacco extract) compared to the normal group, p<0.001, **, *** are compared to the control group The total number of BAL cells in the radish radish extract administration group or the positive control group of the present invention was statistically significantly decreased, ** is p <0.01, and *** is p <0.001.
Figure 7 is the result of confirming the number of neutrophils in BAL after administering the storus extract of the present invention to an animal model with respiratory injury. ### indicates a statistically significant increase in the number of neutrophils in the BAL of the respiratory injury control group induced by LPS + CS (standard tobacco extract) compared to the normal group, p<0.001, and *** is the stork of the present invention compared to the control group The number of neutrophils in the BAL of the shepherd's purse extract administration group or the positive control group was statistically significantly decreased, p<0.001.
8 is a result of confirming the contents of IL-1α, TNF-α, IL-17, MIP2, and CXCL-1 in BALF after administering the extract of the present invention to an animal model with respiratory injury. ##, ### are statistically significant in the content of IL-1α, TNF-α, IL-17, MIP2, and CXCL-1 in the BALF of the control group with respiratory injury induced by LPS+CS (standard tobacco extract) compared to the normal group That is, ## is p <0.01, ### is p <0.001. *, ** indicates that the contents of IL-1α, TNF-α, IL-17, MIP2, and CXCL-1 in BALF were statistically significantly decreased in the group treated with the radish radish extract of the present invention or the positive control group compared to the control group, * is p<0.05, and ** is p<0.01.
Figure 9 shows the results of confirming the expression levels of TNF-α, MIP2, CXCL-1, and MUC5AC genes in lung tissues after administering the wild horseradish extract of the present invention to a respiratory injury animal model. ##, ### indicates a statistically significant increase in the expression levels of TNF-α, MIP2, CXCL-1, and MUC5AC genes in the lung tissue of the control group with respiratory injury induced by LPS+CS (standard tobacco extract) compared to the normal group. , ## is p<0.01, ### is p<0.001. *, ** indicates a statistically significant decrease in TNF-α, MIP2, CXCL-1, and MUC5AC gene expression levels in the lung tissues of the radish radish extract administration group or positive control group of the present invention compared to the control group, * is p <0.05 , ** is p<0.01.
10 shows the results of H&E staining and MT staining confirming the inhibition of pathological damage to lung tissue after administering the extract of the present invention to an animal model with respiratory injury.
본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방 또는 개선용 건강기능식품 조성물에 관한 것이다.The present invention relates to a health functional food composition for preventing or improving respiratory diseases containing an extract of Dorado radish as an active ingredient.
상기 호흡기 질환은 천식, 만성폐쇄성폐질환, 기관지염, 인후염, 편도염 및 후두염으로 이루어진 군에서 선택되는 것이 바람직하지만 이에 한정하는 것은 아니다.The respiratory disease is preferably selected from the group consisting of asthma, chronic obstructive pulmonary disease, bronchitis, sore throat, tonsillitis and laryngitis, but is not limited thereto.
상기 황새냉이 추출물은 황새냉이의 전초를 추출한 것이 바람직하지만 이에 한정하지 않고, 필요에 따라 특정부위를 채택하여 사용할 수 있다.It is preferable that the extract of Stork radish is extracted from the outpost of Stork radish, but is not limited thereto, and may be used by adopting a specific part as needed.
상기 황새냉이 추출물은 하기의 단계를 포함하는 방법에 의해 제조할 수 있으나, 이에 한정하지 않는다:The raspberry extract may be prepared by a method comprising the following steps, but is not limited thereto:
(1) 건조 황새냉이에 추출용매를 가하여 추출하는 단계;(1) extracting by adding an extraction solvent to dried horseradish;
(2) 단계 (1)의 추출액을 여과하는 단계; 및 (2) filtering the extract of step (1); and
(3) 단계 (2)의 여과한 추출액을 건조하여 추출물을 제조하는 단계. (3) preparing an extract by drying the filtered extract of step (2).
상기 단계 (1)에서 추출용매는 물, C1~C4의 저급 알코올 또는 이들의 혼합물 중에서 선택하는 것이 바람직하며, 더 바람직하게는 물 또는 에탄올이고, 더욱더 바람직하게는 에탄올이지만 이에 한정하지 않는다. 상기 제조방법에 있어서, 추출방법은 열수 추출, 침지 추출, 환류 냉각 추출 및 초음파 추출 등의 당 업계에 공지된 모든 통상적인 방법을 이용할 수 있다. 상기 추출용매는 황새냉이 중량의 1~20배 첨가하여 추출하는 것이 바람직하다. 추출온도는 20~100℃인 것이 바람직하나 이에 한정하지 않는다. 또한, 추출시간은 1~5시간인 것이 바람직하며, 1~3시간이 더욱 바람직하지만 이에 한정하지 않는다. 상기 단계 (3)에서, 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조하는 것이 바람직하며, 더 바람직하게는 동결건조이나 이에 한정하지 않는다.In the step (1), the extraction solvent is preferably selected from water, C 1 ~ C 4 lower alcohol or mixtures thereof, more preferably water or ethanol, and still more preferably ethanol, but is not limited thereto. In the above production method, as the extraction method, all conventional methods known in the art such as hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction may be used. It is preferable to extract the extraction solvent by adding 1 to 20 times the weight of the horseradish. The extraction temperature is preferably 20 to 100 ° C, but is not limited thereto. In addition, the extraction time is preferably 1 to 5 hours, more preferably 1 to 3 hours, but is not limited thereto. In the step (3), drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, more preferably freeze drying, but not limited thereto.
상기 건강기능식품 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조되는 것이 바람직하지만 이에 한정하는 것은 아니다. 본 발명의 건강기능식품 조성물은 황새냉이 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 혼합하여 제조될 수 있고, 통상적인 방법에 따라 적절하게 제조될 수 있다. 상기 황새냉이 추출물을 첨가할 수 있는 식품의 예로는 캐러멜, 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 중에서 선택된 어느 하나의 형태일 수 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다. 즉, 상기 식품의 종류에는 특별한 제한은 없다. 상기 건강기능식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 및 천연 풍미제, 착색제 및 증진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 또한, 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 상기의 성분은 독립적으로 또는 조합하여 사용할 수 있다. The health functional food composition is preferably prepared in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage, but is not limited thereto. The health functional food composition of the present invention may be prepared by adding the extract of Dorsal japonica as it is or mixing it with other foods or food ingredients, and may be appropriately prepared according to a conventional method. Examples of foods to which the radish radish extract can be added include caramel, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, It may be in the form of any one selected from tea, drinks, alcoholic beverages and vitamin complexes, and includes all health functional foods in the conventional sense. That is, there is no particular limitation on the type of food. The health functional food composition includes various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners , pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, and the like. It may also contain fruit flesh for the preparation of natural fruit juices and vegetable beverages. The above components may be used independently or in combination.
또한, 본 발명의 건강기능식품 조성물은 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있으며, 상기 천연 탄수화물은 포도당, 과당과 같은 단당류, 말토스, 슈크로스와 같은 이당류, 덱스트린, 사이클로 덱스트린과 같은 다당류, 자일리톨, 소르비톨, 에리트리톨 등의 당 알코올이다. 상기 천연 탄수화물의 비율은 크게 중요하지 않지만, 본 발명의 조성물 100g에 대하여, 0.01~0.04g인 것이 바람직하고, 더욱 바람직하게는 0.02~0.03g을 포함하는 것이지만 이에 한정하지 않는다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.In addition, the health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional components, and the natural carbohydrates may include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, dextrin, and cyclosaccharides. polysaccharides such as dextrin, sugar alcohols such as xylitol, sorbitol, and erythritol. The ratio of the natural carbohydrates is not very important, but is preferably 0.01 to 0.04 g, more preferably 0.02 to 0.03 g, with respect to 100 g of the composition of the present invention, but is not limited thereto. As the sweetener, natural sweeteners such as thaumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame may be used.
또한, 본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방 또는 치료용 약학 조성물에 관한 것이다.In addition, the present invention relates to a pharmaceutical composition for the prevention or treatment of respiratory diseases containing the extract of radish radish as an active ingredient.
본 발명에 따른 황새냉이 추출물을 포함하는 약학조성물은 캡슐제, 산제, 과립제, 정제, 현탁액, 에멀젼, 시럽 및 에어로졸 중에서 선택된 어느 하나의 제형인 것이 바람직하지만 이에 한정하지 않는다. 상기 황새냉이 추출물 이외에 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더 포함할 수 있으며, 황새냉이 추출물을 포함하는 약학 조성물에 포함될 수 있는 담체, 부형제 또는 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 본 발명의 황새냉이 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 황새냉이 추출물을 포함하는 약학 조성물은 1일 0.0001~100㎎/㎏으로, 바람직하게는 0.001~10㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한 번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The pharmaceutical composition containing the extract of Dorado radishes according to the present invention is preferably in any one formulation selected from capsules, powders, granules, tablets, suspensions, emulsions, syrups and aerosols, but is not limited thereto. In addition to the raspberry extract, a pharmaceutically acceptable carrier, excipient or diluent may be further included, and carriers, excipients or diluents that may be included in the pharmaceutical composition containing the raspberry extract include lactose, dextrose, sucrose , oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate , propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. A preferred dosage of the extract of radish radish of the present invention varies depending on the condition and body weight of the patient, the severity of the disease, the type of drug, the route of administration and the period of administration, but can be appropriately selected by those skilled in the art. However, for a desirable effect, the pharmaceutical composition containing the extract of the radish radish of the present invention is preferably administered at 0.0001 to 100 mg/kg per day, preferably at 0.001 to 10 mg/kg. Administration may be administered once a day, or may be administered in several divided doses. The dosage is not intended to limit the scope of the present invention in any way.
또한, 본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방 또는 치료용 수의학적 조성물에 관한 것이다.In addition, the present invention relates to a veterinary composition for the prevention or treatment of respiratory diseases containing the extract of Dorado radish as an active ingredient.
본 발명의 수의학적 조성물은 통상의 방법에 따른 적절한 부형제 및 희석제를 더 포함할 수 있다. 본 발명의 수의학적 조성물에 포함될 수 있는 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시 벤조에이트, 탈크, 마그네슘 스테아레이트, 세탄올, 스테아릴알콜, 유동파라핀, 솔비탄모노스테아레이트, 폴리소르베이트 60, 메칠파라벤, 프로필파라벤 및 광물유를 들 수 있다. 본 발명에 따른 수의학적 조성물은 충진제, 항응집제, 윤활제, 습윤제, 향신료, 유화제, 방부제 등을 추가로 포함할 수 있는데, 본 발명에 따른 수의학적 조성물은 동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 잘 알려진 방법을 사용하여 제형화될 수 있고, 제형은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 용액, 시럽, 에어로졸, 연질 또는 경질 젤라틴 캅셀, 좌제, 멸균 주사용액, 멸균 외용제 등의 형태일 수 있다. 본 발명에 따른 수의학적 조성물의 유효한 양은 동물의 개체에 따라 적절하게 선택할 수 있다. 질환 내지 상태의 중증도, 개체의 연령, 체중, 건강상태 또는 성별에 따른 본 발명의 유효성분에 대한 민감도, 투여 경로, 투여 기간, 상기 조성물과 배합 또는 동시 사용되는 다른 조성물을 포함한 요소 및 기타 생리 내지 수의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.The veterinary composition of the present invention may further include appropriate excipients and diluents according to conventional methods. Excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate ,
또한, 본 발명은 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방 또는 개선용 사료첨가제에 관한 것이다.In addition, the present invention relates to a feed additive for the prevention or improvement of respiratory diseases containing a storus radish extract as an active ingredient.
본 발명의 사료 첨가제는 사료관리법상의 보조사료에 해당한다. 본 발명에서 용어 '사료'는 동물이 먹고, 섭취하며, 소화시키기 위한 또는 이에 적당한 임의의 천연 또는 인공 규정식, 한끼식 등 또는 상기 한 끼 식의 성분을 의미할 수 있다. 상기 사료의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용되는 사료를 사용할 수 있다. 상기 사료의 비제한적인 예로는, 곡물류, 근과류, 식품 가공 부산물류, 조류, 섬유질류, 제약 부산물류, 유지류, 전분류, 박류 또는 곡물 부산물류 등과 같은 식물성 사료; 단백질류, 무기물류, 유지류, 광물성류, 유지류, 단세포 단백질류, 동물성 플랑크톤류 또는 음식물 등과 같은 동물성 사료를 들 수 있다. 이들은 단독으로 사용되거나 2종 이상을 혼합하여 사용될 수 있다.The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act. In the present invention, the term 'feed' may mean any natural or artificial diet, one meal, etc., or a component of the one meal meal, for or suitable for the animal to eat, ingest, and digest. The type of feed is not particularly limited, and feeds commonly used in the art may be used. Non-limiting examples of the feed include vegetable feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal or grain by-products; Animal feed such as proteins, inorganic materials, oils, mineral oils, oils, single cell proteins, zooplankton, or food may be mentioned. These may be used alone or in combination of two or more.
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다. Hereinafter, the present invention will be described in more detail using examples. These examples are only for explaining the present invention in more detail, and it is obvious to those skilled in the art that the scope of the present invention is not limited thereto.
실시예 1. 황새냉이 추출물의 제조Example 1. Preparation of Stove radish extract
건조 황새냉이 전초를 70%(v/v) 에탄올로 2시간 동안 2회 환류 추출한 후 추출액을 여과하고 여과액을 감압농축, 건조하여 추출물을 각각 수득하였다.After refluxing the dried radish root extract twice for 2 hours with 70% (v/v) ethanol, the extract was filtered, and the filtrate was concentrated under reduced pressure and dried to obtain extracts, respectively.
실시예 2. 기관지 상피세포(BEAS-2B)에서 호흡기 염증 억제 활성 확인Example 2. Confirmation of respiratory inflammatory activity in bronchial epithelial cells (BEAS-2B)
황새냉이 추출물의 호흡기 염증 억제 활성은 인체 기관지 상피세포주를 이용하여 염증유발 케모카인 RANTES의 분비 억제 활성을 평가하였다. The inhibitory activity of the inflammatory chemokine, RANTES, was evaluated using human bronchial epithelial cell lines.
FBS(fetal bovine serum) 및 PS(penicillin-streptomycin)를 첨가한 DMEM(Dulbecco's modified eagle's medium)으로 인체 기관지 상피세포주인 BEAS-2B(human bronchial epithelial cell, ATCC, USA) 세포를 배양하였으며, BEAS-2B (5×104 cells/well) 세포를 96웰 플레이트에 10%가 포함된 DMEM 배지에 18시간 배양한 후, 배지를 제거하여 혈청-프리 DMEM으로 배지를 교체하고, 100 및 200㎍/㎖의 황새냉이 추출물과 10ng/㎖의 TNF-α를 동시 처리하여 24시간 동안 배양하였다. RANTES 분비량은 ELISA 키트(R&D systems, USA)를 이용하여 제조사의 방법에 따라 세포 상등액에 존재하는 RANTE의 분비량을 측정하였다. 통계적 차이는 스튜던트 t-테스트를 이용하여 유의성을 평가하였다.BEAS-2B (human bronchial epithelial cell, ATCC, USA) cells were cultured with DMEM (Dulbecco's modified eagle's medium) supplemented with FBS (fetal bovine serum) and PS (penicillin-streptomycin). (5×10 4 cells/well) After culturing the cells in a 96-well plate in DMEM medium containing 10% for 18 hours, the medium was removed and the medium was replaced with serum-free DMEM, and 100 and 200 μg/ml of The extract was simultaneously treated with 10 ng/ml of TNF-α and cultured for 24 hours. The amount of RANTES secretion was measured according to the manufacturer's method using an ELISA kit (R&D systems, USA) to measure the amount of RANTE secretion present in the cell supernatant. Statistical differences were assessed for significance using Student's t-test.
그 결과 도 1에 개시한 바와 같이, 대조군(Control) 대비 TNF-α처리군에서 RANTES 생성량이 통계적으로 유의미하게 증가하였고, 이에 대비하는 본 발명의 황새냉이 추출물을 처리한 군 및 양성대조군(Dexa)에서는 RANTES 생성량이 통계적으로 유의미하게 감소하였다.As a result, as shown in FIG. 1, the amount of RANTES production was statistically significantly increased in the TNF-α treatment group compared to the control group (Control), and in contrast to this, the group treated with the radish radish extract of the present invention and the positive control group (Dexa) In , RANTES production was statistically significantly reduced.
실시예 3. 기관지상피세포에서 LPS로 염증을 유도한 후, 염증성 사이토카인 IL-6, TNF-α, 점액 분비 단백질 MUC5AC 발현량 변화 확인Example 3. After inducing inflammation with LPS in bronchial epithelial cells, inflammatory cytokines IL-6, TNF-α, mucus secretion protein MUC5AC expression level change confirmation
LPS로 염증을 유도한 인체 기관지 상피세포주에서 염증성 사이토카인 IL-6, TNF-α, 점액 분비 단백질 MUC5AC 발현량 변화를 평가하였다. Changes in the expression levels of inflammatory cytokines IL-6, TNF-α, and mucus secretion protein MUC5AC were evaluated in human bronchial epithelial cell lines in which inflammation was induced by LPS.
인체 기관지 상피세포주인 BEAS-2B(human bronchial epithelial cell, ATCC, USA) 세포는 FBS, 페니실린-스트렙토마이신(PS)를 첨가한 DMEM 배지에 18시간 배양한 후, 배지를 제거하여 혈청-프리 DMEM으로 배지를 교체하고, 50㎍/㎖의 황새냉이 추출물 및 20㎍/㎖의 LPS를 처리하여 24시간 배양하였다. 24시간 후 세포 상층액을 회수하여 IL-6, TNF-α 및 MUC5AC 발현량을 측정하였다. BEAS-2B (human bronchial epithelial cell, ATCC, USA) cells, a human bronchial epithelial cell line, were cultured in DMEM medium supplemented with FBS and penicillin-streptomycin (PS) for 18 hours, and then the medium was removed and replaced with serum-free DMEM. The medium was replaced, and cultured for 24 hours by treating with 50 μg/ml of Stork radish extract and 20 μg/ml of LPS. After 24 hours, the cell supernatant was recovered and the expression levels of IL-6, TNF-α and MUC5AC were measured.
그 결과, 대조군(CON) 대비 LPS 유도군의 IL-6, TNF-α 및 MUC5AC 발현량이 현저하게 증가하였으나, 이에 대비하여 황새냉이 추출물을 처리한 실험군의 IL-6, TNF-α 및 MUC5AC 발현량은 현저하게 감소하였다(도 2 내지 도 4). As a result, the expression levels of IL-6, TNF-α and MUC5AC in the LPS-induced group were markedly increased compared to the control group (CON). was significantly decreased (Figs. 2 to 4).
실시예 4. LPS+CS(표준 담배 추출물)로 유도한 호흡기 손상모델에서 호흡기 염증 개선 효과 확인Example 4. LPS + CS (Standard Tobacco Extract) Induced Respiratory Injury Model Confirmation of Respiratory Inflammation Improvement Effect
7주령 BALB/c 수컷 생쥐에 LPS+CS(표준 담배 추출물)을 2주간 3회 코와 입을 통하여 50㎕씩 총 100㎕를 흡인시켜 만성폐쇄성폐질환(COPD)를 유발시켰다. 실험군은 아무런 처리를 하지 않은 정상군(Normal), COPD 유도물질을 처리한 대조군(Control), COPD 유도물질과 양성대조군 덱사메타손(3mg/kg) 투여군, COPD 유도물질과 황새냉이 추출물(200mg/kg) 투여군(CF 200), COPD 유도물질과 황새냉이 추출물(100 mg/kg) 투여군(CF 100)으로 하였다. 약물은 14일 동안 매일 경구투여하였고, 실험이 끝난 후 각 실험군의 마우스 폐포세척액(BALF) 및 폐조직을 분리하였다(도 5). Chronic obstructive pulmonary disease (COPD) was induced in 7-week-old BALB/c male mice by inhaling 50 μl of LPS+CS (standard tobacco extract) through the nose and mouth three times for two weeks. The experimental group was a normal group without any treatment, a control group treated with a COPD inducer, a COPD inducer and a positive control dexamethasone (3mg/kg) administered group, a COPD inducer and a radish extract (200mg/kg) The administration group (CF 200) and the COPD inducer and radish radish extract (100 mg/kg) administration group (CF 100) were selected. The drug was administered orally every day for 14 days, and after the experiment, mouse alveolar lavage fluid (BALF) and lung tissue of each experimental group were separated (FIG. 5).
(1) 기관지 폐포 세척액 분리(1) Separation of bronchoalveolar lavage fluid
실험 마지막 날에 채혈한 후, 개흉하여 기도를 노출시켜 FBS free DMEM 배지 1㎖을 넣은 주사기를 기관지 (trachea)에 삽입하여 주입시키고, 끈으로 묶어 고정한 후에 기관지 폐포세척을 3회 순환하여 세척액(BALF)을 얻었다. 기관지폐포 세척액을 4℃, 2,000rpm, 5분 동안 원심분리한 후에, 상층액은 세포원심분리를 측정하기 위해 냉동보관하였고, BALF에서 분리한 세포는 ACK 액을 3분 동안 처리하여 적혈구를 용해시키고, 다시 1% FBS 프리 DMEM 배양액으로 세척한 후, 혈구계수기를 사용하여 총 세포수를 측정하였다.After blood collection on the last day of the experiment, open the thorax to expose the airway, insert a syringe containing 1 ml of FBS-free DMEM medium into the trachea and inject it, tie it with a string and fix it. ) was obtained. After centrifugation of the bronchoalveolar lavage fluid at 4°C, 2,000 rpm for 5 minutes, the supernatant was stored frozen to measure cell centrifugation, and the cells isolated from BALF were treated with ACK solution for 3 minutes to lyse red blood cells. , After washing again with 1% FBS-free DMEM culture medium, the total cell number was measured using a hemocytometer.
(2) 기관지 폐포 세척액(BALF) 분리 및 총 호중구 세포 수 확인(2) Isolation of bronchoalveolar lavage fluid (BALF) and determination of total neutrophil cell count
혈액을 채혈한 후 해부하여 호중구의 BALF 내 세포 계수를 위해 원심분리 후. 침전된 혈구를 분리하여 0.04% 트리판블루(trypan blue)로 염색한 후 총세포수를 측정하였다. Diff-Quick 염색(Romanowsky stain)을 3회에 걸쳐 처리하였고, 이후 PBS로 2회 세척한 후, 군당 9개의 슬라이드를 제작하여 400× 배율의 광학현미경(Light microscope, Nikon, Japan)을 통해 계수하였다.Blood was drawn, dissected and centrifuged for cell count in BALF of neutrophils. The precipitated blood cells were separated, stained with 0.04% trypan blue, and the total cell number was measured. Diff-Quick staining (Romanowsky stain) was treated three times, then washed twice with PBS, and nine slides per group were prepared and counted through a light microscope (Light microscope, Nikon, Japan) at 400× magnification. .
그 결과 생쥐에 LPS와 표준담배추출물을 INT 방법으로 주입한 대조군에서 호중구 수가 현저하게 증가하였고, 이 결과로부터 폐에서의 염증 수치가 증가한 것으로 판단하였다. As a result, the number of neutrophils increased significantly in the control group injected with LPS and standard tobacco extract by INT method, and from this result, it was judged that the level of inflammation in the lungs increased.
또한 양성대조군인 덱사메타손 투여군 및 황새냉이 추출물(CF) 투여군에서는 BAL 총 세포수와 호중구 수가 유의미하게 감소하였다(도 6 및 도 7). In addition, in the positive control group, dexamethasone-administered group and radish radish extract (CF)-administered group, the BAL total cell number and neutrophil count were significantly decreased (FIGS. 6 and 7).
(3) 효소면역분석법(ELISA)(3) enzyme immunoassay (ELISA)
BALF 내의 IL-1α, TNF-α, IL-17, MIP2, CXCL-1의 양을 측정하기 위해 ELISA를 수행하였다. 포획 항체를 넣고, 4℃에서 밤샘(overnight)한 후, 세척용 완충용액으로 4회 세척하였다. 비오틴이 결합된 항체 시약을 각각의 웰에 100㎕씩 처리하여 1시간 동안 실온에서 반응시킨 후 2회 세척한 다음, 스트렙타비딘-HRP 용액을 각각의 웰에 100㎕씩 처리하여 1시간 동안 실온에서 반응시킨 후에 다시 세척용 완충용액으로 2회 세척하였다. 여기에 기질용액을 100㎕씩 처리하여 20분 동안 반응시킨 후에, 50㎕의 반응정지 용액을 처리하여 반응을 종결시킨 뒤 450nm에서 흡광도를 측정하였다.ELISA was performed to measure the amounts of IL-1α, TNF-α, IL-17, MIP2, and CXCL-1 in BALF. After the capture antibody was added, and overnight at 4° C., the cells were washed 4 times with a washing buffer. 100 μl of biotin-conjugated antibody reagent was treated in each well, reacted at room temperature for 1 hour, washed twice, and then treated with 100 μl of streptavidin-HRP solution in each well and incubated at room temperature for 1 hour After the reaction, it was washed twice with a washing buffer solution. Here, 100 μl of the substrate solution was treated and reacted for 20 minutes, and then the reaction was terminated by treatment with 50 μl of the reaction stop solution, and the absorbance was measured at 450 nm.
그 결과, BALF에서 염증관련 사이토카인 케모카인인 IL-1α, TNF-α, IL-17, MIP2, CXCL-1의 생산량은 LPS+CS(표준 담배 추출물) 유도 대조군에서 모두 증가하였고, 이에 대비하여 양성대조군과 황새냉이 추출물(CF) 투여군에서는 통계적으로 유의미하게 감소하였다(도 8).As a result, the production of IL-1α, TNF-α, IL-17, MIP2, and CXCL-1, which are inflammation-related cytokines and chemokines, in BALF were all increased in the LPS+CS (standard tobacco extract) induced control group. There was a statistically significant decrease in the control group and the radish radish extract (CF)-administered group (FIG. 8).
(4) 폐조직에서 TNF-α, MIP2, CXCL-1, MUC5AC 유전자 발현량 확인(4) Confirmation of TNF-α, MIP2, CXCL-1, and MUC5AC gene expression levels in lung tissue
생쥐의 폐조직을 적출한 후에 RNA 추출용액 500㎕를 넣고 용해될 때까지 분쇄하였다. 13,000rpm으로 원심분리한 후에 에탄올로 수세하고 건조하여 RNA를 추출하였다. 추출한 RNA는 first strand cDNA 합성에 사용하였다. After extracting the lung tissue of the mouse, 500 μl of RNA extraction solution was added and ground until dissolved. After centrifugation at 13,000 rpm, RNA was extracted by washing with ethanol and drying. The extracted RNA was used for first strand cDNA synthesis.
합성한 cDNA를 실시간 중합연쇄반응은 Applied Biosystem 7500 Real-Time PCR 시스템(Applied Biosystems, USA)를 이용하여 수행하였다. TNF-α, MIP2, CXCL-1, MUC5AC 프라이머를 사용하였으며 G3PDH 프로브(VIC, Applied Biosystems, USA)를 사용하였다. 실시간 중합연쇄반응 조건은 프리-변성(pre-denaturation)은 50℃에서 2분, 94℃에서 10분, 및 40사이클을 95℃에서 0.15분, 60℃에서 1분 수행하였다. 황새냉이 추출물 투여군과 대조군은 내부 표준물질(internal strandard)로 G3PDH를 사용하여 RQ(relative quantitative)를 계산하였다. Real-time polymerization of the synthesized cDNA was carried out using an Applied Biosystem 7500 Real-Time PCR system (Applied Biosystems, USA). TNF-α, MIP2, CXCL-1, MUC5AC primers were used, and G3PDH probe (VIC, Applied Biosystems, USA) was used. Real-time polymerization chain reaction conditions were pre-denaturation at 50 °C for 2 minutes, 94 °C for 10 minutes, and 40 cycles at 95 °C for 0.15 minutes and 60 °C for 1 minute. RQ (relative quantitative) was calculated using G3PDH as an internal standard for the radish radish extract administration group and the control group.
그 결과, 염증관련 사이토카인 TNF-α, MIP2, CXCL-1과 점액 단백질 MUC5AC의 유전자 발현은 LPS+CS(표준 담배 추출물) 유도 대조군에서 증가하였고, 양성대조군과 황새냉이 추출물(CF) 투여군에서 유의성 있는 수준으로 감소하였다(도 9).As a result, the gene expression of inflammation-related cytokines TNF-α, MIP2, CXCL-1 and mucin protein MUC5AC increased in the LPS+CS (standard tobacco extract) induced control group, and was significant in the positive control group and the radish radish extract (CF)-administered group. It decreased to a level that is (FIG. 9).
(5) 조직병리검사(5) Histopathological examination
폐조직의 병리적 손상 정도를 관찰하기 위해 폐조직을 절취하여 10% 중화 포르말린(neutral-buffered formalin)에 24시간 동안 고정시킨 다음 알코올로 탈수시키고 파라핀으로 포매하여 블럭을 제작한 다음 마이크로톰으로 4㎛ 두께의 조직절편을 제작하여 H&E(Hematoxylin & Eosin) 염색과 콜라겐 deposition 염색인 M-T(Masson-Trichrome) 염색, 배상세포(goblet cell) 및 분비된 점액질을 관찰하기 위해 PAS 염색을 수행하였다. 염색 후 400× 배율의 광학현미경(Nikon, Japan)을 통해 관찰하였다. In order to observe the degree of pathological damage of lung tissue, the lung tissue was cut and fixed in 10% neutral-buffered formalin for 24 hours, then dehydrated with alcohol, embedded in paraffin to make a block, and then 4㎛ with a microtome. Thick tissue sections were prepared and H&E (Hematoxylin & Eosin) staining, M-T (Masson-Trichrome) staining, collagen deposition staining, and PAS staining were performed to observe goblet cells and secreted mucus. After staining, it was observed through an optical microscope (Nikon, Japan) at 400× magnification.
그 결과, LPS+CS(표준 담배 추출물) 유도 대조군의 H&E 염색법을 통해 염증세포 침윤, 폐세포 벽이 두꺼워진 것을 확인할 수 있었고, M-T 염색법을 통해 교원섬유 증가를 확인할 수 있었다. 이에 대비하여 양성대조군인 덱사메타손 투여군과 황새냉이 추출물(CF) 투여군은 얇은 폐세포 벽과 염증세포 감소, 교원섬유의 감소를 확인할 수 있었다(도 10). As a result, inflammatory cell infiltration and lung cell wall thickening were confirmed through H&E staining of the LPS+CS (standard tobacco extract) induced control group, and collagen fiber increase was confirmed through M-T staining. In contrast, in the positive control group, the dexamethasone-administered group and the dorado radish extract (CF)-administered group, thin lung cell walls, reduction of inflammatory cells, and reduction of collagen fibers were confirmed (FIG. 10).
[통계처리][Statistical Processing]
결과는 평균±오차로 기록하였고, 유의성 검증은 스튜던트 t-테스트 및 일원분석 ANOVA에 따른 던컨의 다중비교분석법(SPSS statistics version 19.0 statistic software, Inc, IBM, USA)을 이용하여 결정하였다. Results were reported as mean ± error, and significance was determined using Duncan's multiple comparison analysis method (SPSS statistics version 19.0 statistic software, Inc, IBM, USA) followed by Student's t-test and one-way ANOVA.
Claims (9)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210186404 | 2021-12-23 | ||
| KR20210186404 | 2021-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230098053A true KR20230098053A (en) | 2023-07-03 |
Family
ID=86903147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220181540A KR20230098053A (en) | 2021-12-23 | 2022-12-22 | Composition for preventing, ameliorating or treating respiratory disease comprising Cardamine flexuosa extract as effective component |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20230098053A (en) |
| WO (1) | WO2023121334A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011195533A (en) * | 2010-03-23 | 2011-10-06 | Shiseido Co Ltd | Fibroblast proliferation promoter and anti-ageing agent |
| JP2011195534A (en) * | 2010-03-23 | 2011-10-06 | Shiseido Co Ltd | Hyaluronic acid production promoter, anti-ageing agent and wrinkle-ameliorating agent |
| KR101863731B1 (en) * | 2017-05-18 | 2018-06-01 | 충남대학교산학협력단 | Composition for preventing, improving or treating prostate disease comprising extract of Cardamine scutata as effective component |
| KR20210120422A (en) * | 2020-03-26 | 2021-10-07 | 애경산업(주) | Cosmetic composition for skin moisturizing comprising extract of Cardamine amaraeformis |
-
2022
- 2022-12-22 WO PCT/KR2022/021047 patent/WO2023121334A1/en unknown
- 2022-12-22 KR KR1020220181540A patent/KR20230098053A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023121334A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101344013B1 (en) | Pharmaceutical composition for prevention and treatment of chronic obstructive pulmonary disease comprising extract of Lilium lancifolium Thunberg as an active ingredient | |
| EP3560506A1 (en) | Pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as effective ingredient for preventing or treating inflammatory bowel disease | |
| KR101397841B1 (en) | Composition for Prevention or Treatment of Inflammatory Pulmonary Diseases Comprising Alisma orientale extract | |
| KR101434464B1 (en) | Composition comprising extracts of Fructus Mume for prevention or treatment of dementia | |
| KR102119855B1 (en) | Composition for preventing, ameliorating or treating inflammatory disease comprising Zanthoxylum schihifolium oil as effective component | |
| EP2875823B1 (en) | Pharmaceutical composition for preventing and treating chronic obstructive pulmonary diseases, containing phyllostachys nigra munro var. henosis stapf extract as active ingredient | |
| KR102197445B1 (en) | Composition of the extract of combined herb CGE for preventing and treating respiratory inflammation | |
| KR101357675B1 (en) | Pharmaceutical composition for prevention and treatment of chronic obstructive pulmonary disease comprising extract of Rhus javanica Linne as an active ingredient | |
| KR101879596B1 (en) | Composition for preventing, improving or treating respiratory inflammatory disease comprising Chamaecyparis obtusa essential oil as effective component | |
| KR20200021738A (en) | Composition comprising Forsythia velutina extract for preventing, improving or treating respiratory disease | |
| KR20230098053A (en) | Composition for preventing, ameliorating or treating respiratory disease comprising Cardamine flexuosa extract as effective component | |
| KR101764756B1 (en) | a composition comprising an extract of Gynura procumbens as an active ingredient for preventing or treating inflammation or allergy | |
| KR101651924B1 (en) | Composition for curing asthma containing extract of salvia plebeia leaft and extract of fermented allium hookeri root | |
| KR20230098052A (en) | Composition for preventing, ameliorating or treating respiratory disease comprising Lysimachia mauritiana extract as effective component | |
| KR20230096889A (en) | Composition for preventing, ameliorating or treating respiratory disease comprising Carpesium sp. plant extract as effective component | |
| WO2023287151A1 (en) | Composition for preventing, alleviating, or treating respiratory diseases, comprising fermented centella asiatica extract as active ingredient | |
| KR20230096888A (en) | Composition for preventing, ameliorating or treating respiratory disease comprising Cacalia adenostyloides extract as effective component | |
| KR102652888B1 (en) | Composition for preventing, improving or treating chronic obstructive pulmonary disease comprising Bupleurum falcatum extract as effective component | |
| KR102270501B1 (en) | Composition for preventing, ameliorating or treating respiratory disease comprising Siraitia grosvenori extract as effective component | |
| KR102671544B1 (en) | Composition for relieving stress and enhancing immune comprising medicinal herb complex extract as effective component | |
| KR20230167297A (en) | Composition for preventing, ameliorating or treating respiratory disease comprising Tilia insularis extract as effective component | |
| KR102487701B1 (en) | Centella asiatica extract for bronchitis or respiratory disease and composition comprising the same as an active ingredient and use thereof | |
| KR20180042729A (en) | The composition containing the ethanol extracts of Ramulus mori for preventing or treating intestinal diseases | |
| KR20230149563A (en) | Composition for preventing, ameliorating or treating allergic respiratory disease comprising Pulsatilla koreana extract as effective component | |
| KR101784370B1 (en) | Composition for prevention or treatment of atopic dermatitis comprising aronia and moringa extract |